Based on the reported response of 231-BO cells to combined AKT/mTOR inhibition in vitro, we suggest that an isoform-specific inhibition of AKT could be a promising therapeutical approach in bone metastasis of breast cancer. The gene discussed is MTOR; the disease is breast carcinoma.